Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib continuation or reintroduction plus chemotherapy versus chemotherapy alone in previously treated advanced soft tissue sarcoma
ChiCTR2400089657Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anlotinib in soft tissue sarcoma (STS) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Median progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2400089657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089657.